Cancer Biology

Research output

Research output per year 1999 2012 2013 2017 2019 2020 2021 2022 2024

• 117 Article
• 14 Letter
• 9 Review article
• 6 Chapter
• 3 More
  • 2 Comment/debate
  • 1 Short survey

Research output per year

Research output per year

Search results

• 2024

  Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

  Abdelbaky, S. B., Giacopelli, B., Rabe, K. G., Yamaguchi, K., Wu, Y. Z., Yan, H., Shanafelt, T. D., Parikh, S. A., Ding, W., Hampel, P. J., Brown, S., Cerhan, J. R., Vachon, C. M., Kay, N. E., Hanson, C. A., Parker, A. S., Braggio, E., Slager, S. L. & Oakes, C. C., 2024, (Accepted/In press) In: Blood.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphocytosis 99%
  • Epigenomics 66%
  • B-Lymphocytes 58%
  • B-Cell Chronic Lymphocytic Leukemia 50%
  • Immunoglobulin Light Chains 13%

• Superior detection rate of plasma cell FISH using FACS-FISH

  Gagnon, M. F., Midthun, S. M., Fangel, J. A., Schuh, C. M., Luoma, I. M., Pearce, K. E., Meyer, R. G., Ailawadhi, S., Arribas, M. J., Braggio, E., Fonseca, R., Rajkumar, S. V., Zepeda-Mendoza, C., Xu, X., Greipp, P. T., Timm, M. M., Otteson, G. E., Shi, M., Jevremovic, D., Olteanu, H., & 4 othersPeterson, J. F., Ketterling, R. P., Kumar, S. & Baughn, L. B., Jan 1 2024, In: American journal of clinical pathology. 161, 1, p. 60-70 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Fluorescence In Situ Hybridization 100%
  • Plasma Cells 98%
  • Immunoglobulins 87%
  • Flow Cytometry 75%
  • Plasma Cell Neoplasms 63%
• 2023

  BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil

  Mazzonetto, P., Milanezi, F., D’Andrea, M., Martins, S., Monfredini, P. M., dos Santos Silva, J., Perrone, E., Villela, D., Schnabel, B., Nakano, V., Palmero, E. I., Braggio, E., Cavalcanti, T. L., Guida, G., Migliavacca, M. P., Scapulatempo-Neto, C. & Zalcberg, I., May 2023, In: Breast Cancer Research and Treatment. 199, 1, p. 127-136 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Germ-Line Mutation 100%
  • Brazil 80%
  • Cohort Studies 60%
  • Breast Neoplasms 56%
  • Mutation 49%

• Clonal Hematopoiesis of Indeterminate Potential Is Associated with Coronary Microvascular Dysfunction in Early Nonobstructive Coronary Artery Disease

  Akhiyat, N., Lasho, T., Ganji, M., Toya, T., Shi, C. X., Chen, X., Braggio, E., Ahmad, A., Corban, M. T., Stewart, K., Fernandez, J., Xie, Z., Finke, C., Lerman, L. O., Patnaik, M. M. & Lerman, A., May 1 2023, In: Arteriosclerosis, thrombosis, and vascular biology. 43, 5, p. 774-783 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hematopoiesis 100%
  • Coronary Artery Disease 76%
  • Hematopoietic Stem Cells 22%
  • Alleles 16%
  • Adenosine 11%

• Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL

  Griffin, R., Wiedmeier-Nutor, J. E., Parikh, S. A., McCabe, C. E., O’Brien, D. R., Boddicker, N. J., Kleinstern, G., Rabe, K. G., Bruins, L., Brown, S., Campos, C. B. D., Ding, W., Leis, J. F., Hampel, P. J., Call, T. G., Van Dyke, D. L., Kay, N. E., Cerhan, J. R., Yan, H., Slager, S. L., & 1 othersBraggio, E., Jul 11 2023, In: Blood Advances. 7, 13, p. 3169-3179 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Multiple Abnormalities 100%
  • B-Cell Chronic Lymphocytic Leukemia 77%
  • Lymphocytosis 68%
  • Mutation 40%
  • B-Lymphocytes 32%

• Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies

  Mondello, P., Paludo, J., Novak, J. P., Wenzl, K., Yang, Z. Z., Jalali, S., Krull, J. E., Braggio, E., Dasari, S., Manske, M. K., Abeykoon, J. A., Sarangi, V., Kapoor, P., Paulus, A., Reeder, C. B., Ailawadhi, S., Chanan-Khan, A. A., Kyle, R. A., Gertz, M. A., Novak, A. J., & 1 othersAnsell, S. M., Mar 1 2023, In: Clinical Cancer Research. 29, 5, p. 957-970 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Waldenstrom Macroglobulinemia 100%
  • Paraproteinemias 91%
  • Monoclonal Gammopathy of Undetermined Significance 83%
  • Immunoglobulin M 65%
  • Metabolomics 32%

• Relationship among three common hematological premalignant conditions

  Boddicker, N. J., Parikh, S. A., Norman, A. D., Rabe, K. G., Griffin, R., Call, T. G., Robinson, D. P., Olson, J. E., Dispenzieri, A., Rajkumar, V., Kumar, S., Kay, N. E., Hanson, C. A., Cerhan, J. R., Murray, D., Braggio, E., Shanafelt, T. D., Vachon, C. M. & Slager, S. L., Aug 2023, In: Leukemia. 37, 8, p. 1719-1722 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
• 2022

  Assessment of 2-Year Storage Conditions on Protein, RNA, and DNA in Unstained Human Tissue Sections, Including a Novel Multiplex Digital Gene Expression Profiling Method with Implications for Biobanking

  Ramsower, C., Wisner, L., Zellner, K., Glinsmann-Gibson, B., Larsen, B., Mcgrath, M., Maguire, A. & Rimsza, L., Dec 1 2022, In: Biopreservation and Biobanking. 20, 6, p. 473-484 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Gene Expression Profiling 100%
  • Desiccant 69%
  • Paraffin 67%
  • RNA 67%
  • Messenger RNA 63%

• Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis

  Boddicker, N. J., Achenbach, S. J., Parikh, S. A., Kleinstern, G., Braggio, E., Norman, A. D., Rabe, K. G., Vachon, C. M., Lesnick, C. E., Call, T. G., Olson, J. E., Cerhan, J. R., Kay, N. E., Hanson, C. A., Shanafelt, T. D. & Slager, S. L., May 2022, In: Leukemia. 36, 5, p. 1404-1407 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells

  Wang, Z., Yan, H., Boysen, J. C., Secreto, C. R., Tschumper, R. C., Ali, D., Guo, Q., Zhong, J., Zhou, J., Gan, H., Yu, C., Jelinek, D. F., Slager, S. L., Parikh, S. A., Braggio, E. & Kay, N. E., Jul 2022, In: Blood cancer journal. 12, 7, 99.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Chronic Lymphocytic Leukemia 90%
  • Signal Transduction 66%
  • B-Lymphocytes 65%
  • Chromatin 30%
  • PCI 32765 25%

• Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes

  Andrieu, C., McNamee, N., Larkin, A. M., Maguire, A., Menon, R., Mueller-Eisert, J., Horgan, N., Kennedy, S., Gullo, G., Crown, J. & Walsh, N., May 24 2022, In: Medical sciences (Basel, Switzerland). 10, 2

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • DNA Repair 100%
  • DNA Damage 94%
  • Melanoma 89%
  • Mutation 60%
  • Genes 43%

• Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib

  Hampel, P. J., Rabe, K. G., Call, T. G., Ding, W., Leis, J. F., Chanan-Khan, A. A., Kenderian, S. S., Muchtar, E., Wang, Y., Ailawadhi, S., Koehler, A. B., Parrondo, R., Schwager, S. M., Sher, T., Hanson, C. A., Shi, M., Van Dyke, D. L., Braggio, E., Slager, S. L., Kay, N. E., & 1 othersParikh, S. A., Sep 2022, In: Blood cancer journal. 12, 9, 124.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • PCI 32765 100%
  • B-Cell Chronic Lymphocytic Leukemia 71%
  • Disease Progression 53%
  • Survival 12%
  • venetoclax 11%

• CLL-506 Clinical Outcomes Beyond Progression on Ibrutinib in Patients With Chronic Lymphocytic Leukemia

  Hampel, P., Rabe, K., Call, T., Ding, W., Leis, J., Chanan-Khan, A., Kenderian, S., Muchtar, E., Wang, Y., Ailawadhi, S., Koehler, A., Parrondo, R., Schwager, S., Sher, T., Hanson, C., Shi, M., Van Dyke, D., Braggio, E., Slager, S., Kay, N., & 1 othersParikh, S., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S281

  Research output: Contribution to journal › Article › peer-review

  • PCI 32765 100%
  • B-Cell Chronic Lymphocytic Leukemia 71%
  • Survival 33%
  • Disease Progression 19%
  • venetoclax 19%

• Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia

  Hampel, P. J., Rabe, K. G., Call, T. G., Ding, W., Leis, J. F., Kenderian, S. S., Muchtar, E., Wang, Y., Koehler, A. B., Parrondo, R., Schwager, S. M., Shi, M., Braggio, E., Slager, S. L., Kay, N. E. & Parikh, S. A., Oct 2022, In: British journal of haematology. 199, 2, p. 239-244 6 p.

  Research output: Contribution to journal › Article › peer-review

  • venetoclax 100%
  • PCI 32765 93%
  • B-Cell Chronic Lymphocytic Leukemia 66%
  • Survival 13%
  • Therapeutics 10%

• Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome

  Wang, H., Tian, S., Zhao, Q., Blumenschein, W., Yearley, J. H., Secreto, C. R., Sinha, S., Call, T. G., Wang, Y., Parikh, S. A., Kenderian, S. S., He, R., Leis, J. F., Shi, M., Van Dyke, D. L., Kay, N. E., Slager, S. L., Braggio, E., Yan, H. & Ding, W., Apr 2022, In: Hematological Oncology. 40, 2, p. 302-306 5 p.

  Research output: Contribution to journal › Letter › peer-review

• Enhancing Tumor Content through Tumor Macrodissection

  Wisner, L., Larsen, B. & Maguire, A., Feb 2022, In: Journal of Visualized Experiments. 2022, 180, e62961.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haematoxylin 100%
  • Tumors 68%
  • Tissue 57%
  • Nucleic Acid 56%
  • Block Like Crystal 45%

• Genomic landscape of Epstein–Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue

  Rea, B., Liu, Y. C., Maguire, A., Soma, L. A., Bacon, C. M., Bayerl, M. G., Smith, M. H., Barrett, M. T., Swerdlow, S. H. & Gibson, S. E., Jul 2022, In: Modern Pathology. 35, 7, p. 938-945 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Marginal Zone B-Cell Lymphoma 100%
  • Viruses 52%
  • Mutation 14%
  • Bruton type agammaglobulinemia 9%
  • Chromosomes, Human, Pair 18 8%

• Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

  Shanafelt, T. D., Wang, X. V., Hanson, C. A., Paietta, E. M., O'Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., Coutre, S. E., Barr, P. M., Cashen, A. F., Mato, A. R., Singh, A. K., Mullane, M. P., Little, R. F., Erba, H., Stone, R. M., Litzow, M., & 2 othersTallman, M. & Kay, N. E., Jul 14 2022, In: Blood. 140, 2, p. 112-120 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ibrutinib 100%
  • Cyclophosphamide 62%
  • B-Cell Chronic Lymphocytic Leukemia 59%
  • PCI 32765 34%
  • fludarabine 24%

• Manual Construction of a Tissue Microarray using the Tape Method and a Handheld Microarrayer

  Wisner, L., Larsen, B. & Maguire, A., Jun 2022, In: Journal of Visualized Experiments. 2022, 184, e63086.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Microarrays 100%
  • Tapes 89%
  • Tissue 74%
  • Block Like Crystal 59%
  • Paraffins 50%

• Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients

  Arribas, M., Ahmann, G. J., Buckner Petty, S., Braggio, E., Theel, E. S. & Fonseca, R., Feb 1 2022, In: American journal of hematology. 97, 2, p. E69-E72

  Research output: Contribution to journal › Letter › peer-review

• Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans

  Kleinstern, G., Weinberg, J. B., Parikh, S. A., Braggio, E., Achenbach, S. J., Robinson, D. P., Norman, A. D., Rabe, K. G., Boddicker, N. J., Vachon, C. M., Lesnick, C. E., Call, T. G., Brander, D. M., Rassenti, L. Z., Kipps, T. J., Olson, J. E., Cerhan, J. R., Kay, N. E., Furman, R. R., Hanson, C. A., & 2 othersShanafelt, T. D. & Slager, S. L., Jan 2022, In: Leukemia. 36, 1, p. 119-125 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphocytosis 100%
  • B-Cell Chronic Lymphocytic Leukemia 81%
  • African Americans 71%
  • B-Lymphocytes 58%
  • Odds Ratio 22%

• Progression and survival of MBL: a screening study of 10 139 individuals

  Slager, S. L., Parikh, S. A., Achenbach, S. J., Norman, A. D., Rabe, K. G., Boddicker, N. J., Olson, J. E., Kleinstern, G., Lesnick, C. E., Call, T. G., Cerhan, J. R., Vachon, C. M., Kay, N. E., Braggio, E., Hanson, C. A. & Shanafelt, T. D., Oct 13 2022, In: Blood. 140, 15, p. 1702-1709 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphocytosis 100%
  • Haematological 72%
  • B-Lymphocytes 58%
  • Confidence Intervals 18%
  • Neoplasms 11%

• Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers

  Arora, M., Bogenberger, J. M., Abdelrahman, A. M., Yonkus, J., Alva-Ruiz, R., Leiting, J. L., Chen, X., Serrano Uson Junior, P. L., Dumbauld, C. R., Baker, A. T., Gamb, S. I., Egan, J. B., Zhou, Y., Nagalo, B. M., Meurice, N., Eskelinen, E. L., Salomao, M. A., Kosiorek, H. E., Braggio, E., Barrett, M. T., & 8 othersBuetow, K. H., Sonbol, M. B., Mansfield, A. S., Roberts, L. R., Bekaii-Saab, T. S., Ahn, D. H., Truty, M. J. & Borad, M. J., Jan 2022, In: Hepatology. 75, 1, p. 43-58 16 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cyclin-Dependent Kinase 6 100%
  • Biliary Tract Neoplasms 92%
  • Cyclin-Dependent Kinase 4 91%
  • gemcitabine 72%
  • Combination Drug Therapy 65%

• The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis

  Parikh, S. A., Achenbach, S. J., Rabe, K. G., Norman, A. D., Boddicker, N. J., Olson, J. E., Call, T. G., Cerhan, J. R., Vachon, C. M., Kay, N. E., Braggio, E., Hanson, C. A., Slager, S. L. & Shanafelt, T. D., Nov 2022, In: Blood cancer journal. 12, 11, 159.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
• 2021

  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

  Gandhi, M. K., Hoang, T., Law, S. C., Brosda, S., O'Rourke, K., Tobin, J. W. D., Vari, F., Murigneux, V., Fink, L., Gunawardana, J., Gould, C., Oey, H., Bednarska, K., Delecluse, S., Trappe, R. U., Merida de Long, L., Sabdia, M. B., Bhagat, G., Hapgood, G., Blyth, E., & 8 othersClancy, L., Wight, J., Hawkes, E., Rimsza, L. M., Maguire, A., Bojarczuk, K., Chapuy, B. & Keane, C., Mar 18 2021, In: Blood. 137, 11, p. 1468-1477 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Human Herpesvirus 4 100%
  • Immunosuppression 91%
  • Mutation 85%
  • Lymphoma 83%
  • Central Nervous System 74%
  5 Scopus citations

• EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features

  Chapman, J. R., Bouska, A. C., Zhang, W., Alderuccio, J. P., Lossos, I. S., Rimsza, L. M., Maguire, A., Yi, S., Chan, W. C., Vega, F. & Song, J. Y., Sep 2021, In: British journal of haematology. 194, 5, p. 870-878 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Human Herpesvirus 4 88%
  • HIV 61%
  • Mutation 49%
  • B-Lymphocytes 14%

• Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia

  Cox, M. J., Lucien, F., Sakemura, R., Boysen, J. C., Kim, Y., Horvei, P., Manriquez Roman, C., Hansen, M. J., Tapper, E. E., Siegler, E. L., Forsman, C., Crotts, S. B., Schick, K. J., Hefazi, M., Ruff, M. W., Can, I., Adada, M., Bezerra, E., Kankeu Fonkoua, L. A., Nevala, W. K., & 5 othersBraggio, E., Ding, W., Parikh, S. A., Kay, N. E. & Kenderian, S. S., Apr 7 2021, In: Molecular Therapy. 29, 4, p. 1529-1540 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haematological 100%
  • Chimeric Antigen Receptors 94%
  • Extracellular Vesicles 82%
  • B-Cell Chronic Lymphocytic Leukemia 74%
  • T-Lymphocytes 43%

• Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

  Wang, X. V., Hanson, C. A., Tschumper, R. C., Lesnick, C. E., Braggio, E., Paietta, E. M., O'Brien, S., Barrientos, J. C., Leis, J. F., Zhang, C. C., Coutre, S. E., Barr, P. M., Cashen, A. F., Mato, A. R., Singh, A. K., Mullane, M. P., Erba, H., Stone, R., Litzow, M. R., Tallman, M. S., & 2 othersShanafelt, T. D. & Kay, N. E., Dec 30 2021, In: Blood. 138, 26, p. 2810-2827 18 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ibrutinib 100%
  • PCI 32765 83%
  • Cyclophosphamide 78%
  • Progression-Free Survival 50%
  • Rituximab 23%

• Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

  Slager, S. L., Lanasa, M. C., Marti, G. E., Achenbach, S. J., Camp, N. J., Abbasi, F., Kay, N. E., Vachon, C. M., Cerhan, J. R., Johnston, J. B., Call, T. G., Rabe, K. G., Kleinstern, G., Boddicker, N. J., Norman, A. D., Parikh, S. A., Leis, J. F., Banerji, V., Brander, D. M., Glenn, M., & 8 othersFerrajoli, A., Curtin, K., Braggio, E., Shanafelt, T. D., McMaster, M. L., Weinberg, J. B., Hanson, C. A. & Caporaso, N. E., Apr 15 2021, In: Blood. 137, 15, p. 2046-2056 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphocytosis 100%
  • B-Cell Chronic Lymphocytic Leukemia 81%
  • Natural History 76%
  • B-Lymphocytes 58%
  • Incidence 18%

• Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy

  Kretzmer, H., Biran, A., Purroy, N., Lemvigh, C. K., Clement, K., Gruber, M., Gu, H., Rassenti, L., Mohammad, A. W., Lesnick, C., Slager, S. L., Braggio, E., Shanafelt, T. D., Kay, N. E., Fernandes, S. M., Brown, J. R., Wang, L., Li, S., Livak, K. J., Neuberg, D. S., & 7 othersKlages, S., Timmermann, B., Kipps, T. J., Campo, E., Gnirke, A., Wu, C. J. & Meissner, A., Jan 1 2021, In: Blood cancer discovery. 2, 1, p. 54-69 16 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Epigenome 100%
  • B-Cell Chronic Lymphocytic Leukemia 85%
  • Lymphocytosis 78%
  • Disease Progression 64%
  • B-Lymphocytes 46%

• ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

  Vaisitti, T., Arruga, F., Vitale, N., Lee, T. T., Ko, M., Chadburn, A., Braggio, E., Di Napoli, A., Iannello, A., Allan, J. N., Miller, L. L., Lannutti, B. J., Furman, R. R., Jessen, K. A. & Deaglio, S., Jun 17 2021, In: Blood. 137, 24, p. 3365-3377 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haematological 100%
  • Immunoconjugates 93%
  • Heterografts 63%
  • Cytotoxin 50%
  • Cell Death 37%

• The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

  Parikh, S. A., Rabe, K. G., Kay, N. E., Call, T. G., Ding, W., Leis, J. F., Kenderian, S. S., Muchtar, E., Wang, Y., Koehler, A. B., Schwager, S. M., Lesnick, C. E., Kleinstern, G., Van Dyke, D., Hanson, C. A., Braggio, E., Slager, S. L. & Shanafelt, T. D., Jul 15 2021, In: Blood. 138, 2, p. 149-159 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphocytosis 100%
  • B-Cell Chronic Lymphocytic Leukemia 67%
  • B-Lymphocytes 58%
  • Survival 35%
  • Time 27%

• The prognostic significance of del6q23 in chronic lymphocytic leukemia

  Audil, H. Y., Hampel, P. J., Van Dyke, D. L., Achenbach, S. J., Rabe, K. G., Smoley, S. A., Call, T. G., Ding, W., Shi, M., Hanson, C. A., Wang, Y., Muchtar, E., Koehler, A. B., Schwager, S. M., Leis, J. F., Braggio, E., Slager, S. L., Kay, N. E., Kenderian, S. S. & Parikh, S. A., Jun 1 2021, In: American journal of hematology. 96, 6, p. E203-E206

  Research output: Contribution to journal › Letter › peer-review

  Open Access
• 2020

  Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

  Hampel, P. J., Call, T. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., Fonder, A. L., Schwager, S. M., Rabe, K. G., Van Dyke, D. L., Braggio, E., Slager, S. L., Kay, N. E. & Parikh, S. A., Mar 1 2020, In: American journal of hematology. 95, 3, p. E57-E60

  Research output: Contribution to journal › Letter › peer-review
  1 Scopus citations

• Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci

  Yan, H., Tian, S., Kleinstern, G., Wang, Z., Lee, J. H., Boddicker, N. J., Cerhan, J. R., Kay, N. E., Braggio, E. & Slager, S. L., Aug 15 2020, In: Human molecular genetics. 29, 16, p. 2761-2774 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • Chromatin Immunoprecipitation Sequencing 40%
  • Chromatin 27%
  • Interferon Type I 18%
  • Histone Code 17%

• Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma

  Ramsower, C. A., Maguire, A., Robetorye, R. S., Feldman, A. L., Syrbu, S. I., Rosenthal, A. C. & Rimsza, L. M., Dec 2020, In: Journal of Hematopathology. 13, 4, p. 231-238 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mantle-Cell Lymphoma 100%
  • Gene Expression Profiling 39%
  • Fixatives 25%
  • B-Lymphocytes 14%
  • Acids 14%

• Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia

  Hampel, P. J., Call, T. G., Rabe, K. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., Fonder, A. L., Schwager, S. M., Van Dyke, D. L., Braggio, E., Slager, S. L., Kay, N. E. & Parikh, S. A., Nov 1 2020, In: Oncologist. 25, 11, p. 974-980 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • PCI 32765 100%
  • B-Cell Chronic Lymphocytic Leukemia 71%
  • Therapeutics 11%
  • Withholding Treatment 5%
  • Progression-Free Survival 4%
  1 Scopus citations

• Distinct molecular profile of IRF4-rearranged large B-cell lymphoma

  Ramis-Zaldivar, J. E., Gonzalez-Farré, B., Balagué, O., Celis, V., Nadeu, F., Salmerón-Villalobos, J., Andrés, M., Martin-Guerrero, I., Garrido-Pontnou, M., Gaafar, A., Suñol, M., Bárcena, C., Garcia-Bragado, F., Andión, M., Azorín, D., Astigarraga, I., de Ilurdoz, M. S., Sábado, C., Gallego, S., Verdú-Amorós, J., & 20 othersFernandez-Delgado, R., Perez, V., Tapia, G., Mozos, A., Torrent, M., Solano-Páez, P., Rivas-Delgado, A., Dlouhy, I., Clot, G., Enjuanes, A., López-Guillermo, A., Galera, P., Oberley, M. J., Maguire, A., Ramsower, C., Rimsza, L. M., Quintanilla-Martinez, L., Jaffe, E. S., Campo, E. & Salaverria, I., Jan 23 2020, In: Blood. 135, 4, p. 274-286 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Lymphoma 100%
  • Mutation 81%
  • Heterogeneity 59%
  • Non-Hodgkin's Lymphoma 34%
  • Germinal Center 28%
  4 Scopus citations

• Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer

  Arora, M., Bogenberger, J. M., Abdelrahman, A., Leiting, J. L., Chen, X., Egan, J. B., Kasimsetty, A., Lenkiewicz, E., Malasi, S., Uson, P. L. S., Nagalo, B. M., Zhou, Y., Salomao, M. A., Kosiorek, H. E., Braggio, E., Barrett, M. T., Truty, M. J. & Borad, M. J., Jun 1 2020, In: Cancer chemotherapy and pharmacology. 85, 6, p. 1063-1078 16 p.

  Research output: Contribution to journal › Article › peer-review

  • NUC-1031 100%
  • Protide 72%
  • Gemcitabine 61%
  • Biliary Tract Neoplasms 58%
  • gemcitabine 45%
  5 Scopus citations

• Frequent expression of activation-induced cytidine deaminase in diffuse large b-cell lymphoma tissues from persons living with HIV

  Shponka, V., Reveles, C. Y., Alam, S., Jaramillo, M., Maguire, A., Rimsza, L. M. & Kendrick, S., 2020, In: AIDS. 34, 14, p. 2025-2035 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • AICDA (activation-induced cytidine deaminase) 100%
  • Cytidine Deaminase 81%
  • Lymphoma, Large B-Cell, Diffuse 76%
  • HIV 46%
  • DC-specific ICAM-3 grabbing nonintegrin 32%
  1 Scopus citations

• Identification of PIKfyve kinase as a target in multiple myeloma

  De Campos, C. B., Zhu, Y. X., Sepetov, N., Romanov, S., Bruins, L. A., Shi, C. X., Stein, C. K., Petit, J. L., Polito, A. N., Sharik, M. E., Meermeier, E. W., Ahmann, G. J., Armenta, I. D. L., Kruse, J., Bergsagel, P. L., Chesi, M., Meurice, N., Braggio, E. & Stewart, A. K., Jun 1 2020, In: Haematologica. 105, 6, p. 1641-1649 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • APY0201 100%
  • Multiple Myeloma 38%
  • Phosphotransferases 30%
  • Autophagy 22%
  • 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide 16%
  5 Scopus citations

• IKZF1/3 and CRL4^CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma

  Barrio, S., Munawar, U., Zhu, Y. X., Giesen, N., Shi, C. X., Da Viá, M., Sanchez, R., Bruins, L., Demler, T., Müller, N., Haertle, L., Garitano, A., Steinbrunn, T., Danhof, S., Cuenca, I., Barrio-Garcia, C., Braggio, E., Rosenwald, A., Martinez-Lopez, J., Rasche, L., & 5 othersRaab, M. S., Stewart, A. K., Einsele, H., Stühmer, T. & Kortüm, K. M., May 1 2020, In: Haematologica. 105, 5, p. E237-E241

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  5 Scopus citations

• Monosomic Loss of MiR15a/MiR16-1 is a Driver of Multiple Myeloma Proliferation and Disease Progression

  Chesi, M., Stein, C. K., Garbitt, V. M., Sharik, M. E., Asmann, Y. W., Bergsagel, M., Riggs, D. L., Welsh, S. J., Meermeier, E. W., Kumar, S. K., Braggio, E. & Bergsagel, P. L., Jul 1 2020, In: Blood cancer discovery. 1, 1, p. 68-81 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Multiple Myeloma 100%
  • Disease Progression 80%
  • Chromosomes, Human, Pair 13 67%
  • Paraproteinemias 21%
  • Human Chromosomes 19%

• Multiple hypotheses about two mammalian upper dentitions from the Early Cretaceous of Australia

  Rich, T. H., Flannery, T. F., Evans, A. R., White, M., Ziegler, T., Maguire, A., Poropat, S., Trusler, P. & Vickers-Rich, P., 2020, In: Alcheringa. 44, 4, p. 528-536 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • dentition 100%
  • Victoria (Australia) 85%
  • teeth 74%
  • school 74%
  • monotreme 67%

• MYC dysregulation in the progression of multiple myeloma

  MMRF CoMMpass Network, Jan 1 2020, In: Leukemia. 34, 1, p. 322-326 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  24 Scopus citations

• Proteasome subunits differentially control myeloma cell viability and proteasome inhibitor sensitivity

  Shi, C. X., Zhu, Y. X., Bruins, L. A., de Campos, C. B., Stewart, W., Braggio, E. & Stewart, A. K., Oct 1 2020, In: Molecular Cancer Research. 18, 10, p. 1453-1464 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Proteasome Inhibitors 100%
  • Proteasome Endopeptidase Complex 87%
  • Multiple Myeloma 82%
  • Bortezomib 68%
  • Cell Line 32%
  2 Scopus citations

• Recommendations for Tissue Microarray Construction and Quality Assurance

  Glinsmann-Gibson, B., Wisner, L., Stanton, M., Larsen, B., Rimsza, L. & Maguire, A., Apr 19 2020, In: Applied Immunohistochemistry and Molecular Morphology. 28, 4, p. 325-330 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tissue Banks 100%
  • Cost Control 85%
  • Quality Control 66%
  • Acquired Immunodeficiency Syndrome 57%
  • RNA 47%

• Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

  Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., Agius, M. P., Park, J., Manier, S., Bustoros, M., Huynh, D., Capelletti, M., Berrios, B., Liu, C. J., He, M. X., Braggio, E., & 9 othersFonseca, R., Maruvka, Y., Guerriero, J. L., Goldman, M., van Allen, E., McCarroll, S. A., Azzi, J., Getz, G. & Ghobrial, I. M., May 1 2020, In: Nature Cancer. 1, 5, p. 493-506 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • RNA Sequence Analysis 100%
  • Multiple Myeloma 88%
  • Smoldering Multiple Myeloma 71%
  • Immunologic Monitoring 28%
  • T-Lymphocytes 27%

• Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index

  Kleinstern, G., O'Brien, D. R., Li, X., Tian, S., Kabat, B. F., Rabe, K. G., Norman, A. D., Yan, H., Vachon, C. M., Boddicker, N. J., Call, T. G., Parikh, S. A., Bruins, L., Bonolo de Campos, C., Leis, J. F., Shanafelt, T. D., Ding, W., Cerhan, J. R., Kay, N. E., Slager, S. L., & 1 othersBraggio, E., Aug 1 2020, In: American journal of hematology. 95, 8, p. 906-917 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphocytosis 100%
  • B-Cell Chronic Lymphocytic Leukemia 81%
  • Tumor Burden 72%
  • Genes 18%
  • Confidence Intervals 18%
  2 Scopus citations

• Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer

  Walsh, N., Andrieu, C., O’Donovan, P., Quinn, C., Maguire, A., Furney, S. J., Gullo, G. & Crown, J., Oct 13 2020, In: British journal of cancer. 123, 8, p. 1219-1222 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Trastuzumab 100%
  • Whole Exome Sequencing 99%
  • Breast Neoplasms 53%
  • Recurrence 48%
  • Genome 38%